← NAD+ overview

NAD+ Dosage & Reconstitution Guide

⚠ Rapid injection or infusion can cause chest tightness, flushing, severe cramping, nausea, and a racing heart; people with cardiac arrhythmia, uncontrolled hypertension, or who are pregnant should avoid self-administration. Injectable NAD+ is not FDA-approved.

Research and educational use only — not medical advice, and not for human consumption. The figures below are summarized from public sources, product labeling, and community reports, and are not a prescription or a substitute for a qualified clinician.

Typical dose
50-100 mg subcutaneously, often daily or a few times weekly; clinic IV 250-1000 mg per slow infusion.
Route
Subcutaneous injection
Frequency
daily or 3-5x per week
After mixing
250 mg/mL (250000 mcg/mL)

Reconstitution

NAD+ ships as a freeze-dried (lyophilized) powder that has to be mixed with bacteriostatic water before use. Draw 2 mL of bacteriostatic water into a syringe and add it to a 500 mg vial, letting the stream run down the inside wall of the glass rather than blasting the powder directly. Swirl gently — never shake — until the solution is clear, then keep it refrigerated.

Worked example. 2 mL into a 500 mg vial gives a concentration of 250 mg/mL (250000 mcg/mL). A 100 mg dose then works out to 0.4 mL = 40 units on a U-100 insulin syringe. Scale the water volume up or down to make your target dose land on an easy-to-read mark (1 unit = 0.01 mL).

  1. Wipe both vial stoppers (peptide and bacteriostatic water) with an alcohol swab and let them dry.
  2. Draw 2 mL of bacteriostatic water into a syringe.
  3. Inject it slowly against the inside wall of the peptide vial.
  4. Swirl gently until fully dissolved; do not shake.
  5. Label the vial with the contents, concentration, and date, and store it in the refrigerator.

Dosing schedule

Phase Dose Volume Insulin units (U-100) Notes
Assessment 25 mg 0.1 mL 10 units First doses to check sting and tolerance; inject slowly
Common subQ 50 mg 0.2 mL 20 units Typical daily community dose
Standard subQ 100 mg 0.4 mL 40 units Upper subQ dose; inject slowly to limit flushing

Timing & cycling

Inject slowly over 5-10 seconds (longer if it stings), preferably in the morning; slow delivery is the key to reducing flushing, cramping, and nausea.

Cycle length. Often run in 2-4 week blocks or ongoing; many use daily loading then taper to a few times weekly for maintenance.

Storage & handling

Keep the lyophilized (unmixed) vial refrigerated at 2–8 °C (36–46 °F) in a dry, dark place — it tolerates short periods at room temperature during shipping. Once reconstituted, store it at 2–8 °C, never frozen, and use it within about 2–4 weeks (sooner if the solution turns cloudy or discolored). Swab the stopper before every draw and use a fresh needle each time.

Supplies you'll need

  • NAD+ vials — about 8 for an 8-week run at the upper dose
  • Bacteriostatic water — 2 mL per vial (a 10–30 mL multi-dose bottle covers several vials)
  • U-100 insulin syringes (0.3–0.5 mL / 30–50 unit barrels are easiest to read) — roughly 40 for 8 weeks, plus spares
  • Alcohol swabs — one per injection and one per vial draw
  • Sharps container for safe needle disposal

Key points

  • NAD+ is a metabolic coenzyme, not a peptide; injectable use is off-label and largely unregulated.
  • Speed matters more than dose for comfort: the faster it goes in, the worse the flushing and cramps.
  • Powder must be reconstituted with bacteriostatic water and refrigerated after mixing.
  • Larger IV protocols (250-1000 mg) are meant for clinic settings with slow infusion, not quick self-injection.
  • Start at ~25 mg to gauge the sting before working up to 50-100 mg.

What to monitor

Watch heart rate and blood pressure with larger doses, and track injection-site tolerance, sleep, and energy; IV-level dosing should be medically supervised.

Legal & prescription status

Sold as a compounded preparation or research chemical, not an FDA-approved longevity drug; legitimate injectable NAD+ is typically obtained from a compounding pharmacy with a prescription. Presented here as a supplement/cofactor for research and educational context only.

References

  1. IV NAD+ vs nicotinamide riboside tolerability pilot (Front Aging)
  2. Clinical Evidence for Targeting NAD Therapeutically (MDPI, 2020)
  3. Safety and effectiveness of NAD: systematic review (2023)

This guide is for research and educational purposes only. It is not medical advice and does not describe a product approved for human use. Always consult a qualified healthcare professional before considering any peptide protocol.